ABSTRACT
Multidrug-resistant Acinetobacter baumannii (MDR-Ab) is one of the most significant nosocomial pathogens that is being increasingly isolated in healthcare settings worldwide. Owing to its inherent drug-resistant nature, coupled with its ability to readily acquire resistance to other antibiotic classes, there is a real dearth of antibiotics available to treat infections with MDR-Ab. A commercially available library was screened against MDR-Ab BAA-1605 to identify novel inhibitory molecules. The selectivity index of a hit was tested against Vero cells and in vitro efficacy was profiled against a panel of clinical MDR-Ab. The bacteriostatic or bactericidal nature was determined by time-kill experiments, and synergy with clinically approved drugs was determined by the chequerboard method. Additionally, in vivo efficacy was measured in a murine neutropenic A. baumannii thigh infection model. SRI-12742 was identified as a potent active hit, with a minimum inhibitory concentration (MIC) of 4 mg/L against BAA-1605. Its activity was then profiled against a MDR-Ab clinical strain panel (MICs 4 mg/L to >64 mg/L). SRI-12742 exhibited concentration-dependent bactericidal activity and caused an ca. 16 log10 CFU/mL reduction at 10â¯×â¯MIC in 24 h, which is comparable with minocycline. In a murine neutropenic thigh infection model of A. baumannii infection, SRI-12742 reduced CFU counts by ca. 0.9 log10 CFU, which is comparable with polymyxin B. In addition, SRI-12742 synergised with all classes of antibiotics tested. SRI-12742 exhibits all of the criteria necessary to be positioned as a novel lead with potential to be deployed for the treatment of infections caused by MDR-Ab.
Subject(s)
Acinetobacter Infections/drug therapy , Acinetobacter baumannii/drug effects , Anti-Bacterial Agents/pharmacology , Drug Evaluation, Preclinical/methods , Indoles/pharmacology , Acinetobacter baumannii/pathogenicity , Animals , Anti-Bacterial Agents/chemistry , Chlorocebus aethiops , Dose-Response Relationship, Drug , Drug Resistance, Multiple, Bacterial/drug effects , Drug Synergism , Mice, Inbred BALB C , Microbial Sensitivity Tests , Vero CellsABSTRACT
We report that the addition of an host paracaspase MALT1 inhibitor, MI-2, to HIV latently infected ACH-2, Jurkat E4, and J-LAT cells accelerated cell death in the presence of cell stimuli or the protein kinase C agonist, bryostatin 1. MI-2-mediated cell death correlated with the induction of the cellular RNase MCPIP1 and requires the presence of viral component(s). Altogether, the combination of MI-2 and bryostatin 1 displays selective killing of HIV latently infected CD4(+) T cells.
Subject(s)
Acetanilides/pharmacology , Bryostatins/pharmacology , CD4-Positive T-Lymphocytes/drug effects , HIV Infections/drug therapy , HIV-1/drug effects , Neoplasm Proteins/antagonists & inhibitors , Triazoles/pharmacology , CD4-Positive T-Lymphocytes/virology , Caspases/metabolism , Cell Line, Tumor , HIV Infections/virology , Humans , Jurkat Cells , Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein , Neoplasm Proteins/metabolism , Ribonucleases/metabolism , Transcription Factors/metabolism , Virus Activation/drug effects , Virus Latency , Virus Replication/drug effectsABSTRACT
In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.
Subject(s)
Antiviral Agents/pharmacology , Enzyme Inhibitors/pharmacology , Hepacivirus/drug effects , Quinolines/pharmacology , Sulfonamides/pharmacology , Viral Nonstructural Proteins/antagonists & inhibitors , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacokinetics , Dogs , Drug Discovery , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Hepacivirus/enzymology , Humans , Models, Molecular , Quinolines/chemistry , Quinolines/pharmacokinetics , Rats , Sulfonamides/chemistry , Sulfonamides/pharmacokineticsABSTRACT
A novel series of indole/indazole-aminopyrimidines was designed and synthesized with an aim to achieve optimal potency and selectivity for the c-Jun kinase family or JNKs. Structure guided design was used to optimize the series resulting in a significant potency improvement. The best compound (17) has IC50 of 3 nM for JNK1 and 20 nM for JNK2, with greater than 40-fold selectivity against other kinases with good physicochemical and pharmacokinetic properties.
Subject(s)
Indoles/chemistry , Indoles/pharmacology , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Pyrimidines/chemistry , Pyrimidines/pharmacology , Crystallography, X-Ray , Indazoles/chemistry , Indazoles/pharmacology , JNK Mitogen-Activated Protein Kinases/chemistry , Phosphorylation , Structure-Activity RelationshipABSTRACT
A series of amino-pyrimidines was developed based upon an initial kinase cross-screening hit from a CDK2 program. Kinase profiling and structure-based drug design guided the optimization from the initial 1,2,3-benzotriazole hit to a potent and selective JNK inhibitor, compound 24f (JNK1 and 2 IC(50)=16 and 66 nM, respectively), with bioavailability in rats and suitable for further in vivo pharmacological evaluation.
Subject(s)
JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Pyrimidines/chemistry , Pyrimidines/pharmacology , Triazoles/chemistry , Triazoles/pharmacology , Animals , Crystallography, X-Ray , Drug Design , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Models, Molecular , Protein Kinase Inhibitors/chemical synthesis , Pyrimidines/chemical synthesis , Rats , Structure-Activity Relationship , Triazoles/chemical synthesisABSTRACT
A novel series of highly selective JNK inhibitors based on the 4-quinolone scaffold was designed and synthesized. Structure based drug design was utilized to guide the compound design as well as improvements in the physicochemical properties of the series. Compound (13c) has an IC(50) of 62/170 nM for JNK1/2, excellent kinase selectivity and impressive efficacy in a rodent asthma model.
Subject(s)
4-Quinolones/pharmacology , Drug Discovery , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/pharmacology , 4-Quinolones/chemical synthesis , 4-Quinolones/chemistry , Crystallography, X-Ray , Dose-Response Relationship, Drug , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Models, Molecular , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Structure-Activity RelationshipABSTRACT
BACKGROUND AND PURPOSE: It is thought that the anti-inflammatory effects of glucocorticoids (GCs) are largely due to GC receptor (GR)-mediated transrepression of NF-κB and other transcription factors, whereas side effects are caused by activation of gene expression (transactivation). Selective GR modulators (SGRMs) that preferentially promote transrepression should retain anti-inflammatory properties whilst causing fewer side effects. Contradicting this model, we found that anti-inflammatory effects of the classical GC dexamethasone were partly dependent on transactivation of the dual specificity phosphatase 1 (DUSP1) gene. We wished to determine whether anti-inflammatory effects of SGRMs are also mediated by DUSP1. EXPERIMENTAL APPROACH: Dissociated properties of two SGRMs were confirmed using GR- and NF-κB-dependent reporters, and capacity to activate GC-responsive elements of the DUSP1 gene was tested. Effects of SGRMs on the expression of DUSP1 and pro-inflammatory gene products were assessed in various cell lines and in primary murine Dusp1(+/+) and Dusp1(-/-) macrophages. KEY RESULTS: The SGRMs were able to up-regulate DUSP1 in several cell types, and this response correlated with the ability of the compounds to suppress COX-2 expression. Several anti-inflammatory effects of SGRMs were ablated or significantly impaired in Dusp1(-/-) macrophages. CONCLUSIONS AND IMPLICATIONS: Like dexamethasone, SGRMs appear to exert anti-inflammatory effects partly via the up-regulation of DUSP1. This finding has implications for how potentially therapeutic novel GR ligands are identified and assessed.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Benzofurans/pharmacology , Benzoxazines/pharmacology , Dual Specificity Phosphatase 1/metabolism , Pentanols/pharmacology , Quinolines/pharmacology , Receptors, Glucocorticoid/agonists , Animals , Bone Marrow Cells/cytology , Cell Line , Cell Line, Tumor , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Dexamethasone , Dual Specificity Phosphatase 1/deficiency , Dual Specificity Phosphatase 1/genetics , Glucocorticoids , HeLa Cells , Humans , Macrophages/drug effects , Macrophages/metabolism , Mice , Mice, Knockout , NF-kappa B/metabolism , RNA, Messenger/metabolismABSTRACT
Here we report on the discovery of a series of maleimides which have high potency and good selectivity for GSK-3beta. The incorporation of polar groups afforded compounds with good bioavailability. The most potent compound 34 has an IC(50) of 0.6nM for GSK-3beta, over 100-fold selectivity against a panel of other kinases, and shows efficacy in rat osteoporosis models. The X-ray structure of GSK-3beta protein with 34 bound revealed the binding mode of the template and provided insights for future optimization opportunities.
Subject(s)
Glycogen Synthase Kinase 3/antagonists & inhibitors , Indoles/chemistry , Maleimides/chemistry , Protein Kinase Inhibitors/chemistry , Administration, Oral , Animals , Binding Sites , Crystallography, X-Ray , Disease Models, Animal , Drug Discovery , Glycogen Synthase Kinase 3/metabolism , Glycogen Synthase Kinase 3 beta , Indoles/chemical synthesis , Indoles/pharmacokinetics , Maleimides/chemical synthesis , Maleimides/pharmacokinetics , Mice , Protein Kinase C/metabolism , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacokinetics , Rats , Structure-Activity RelationshipABSTRACT
BACKGROUND: Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease. OBJECTIVES/METHODS: A patent literature review is presented of small molecule CCR3 antagonists comprising the years 2004 to the present. The patent searches were conducted using Derwent Discovery (World patent index) and PCT publication databases. RESULTS/CONCLUSION: At least two small molecule compounds have been reported to advance into clinical trials. However, data that support a definitive proof-of-concept in humans have yet to be disclosed. Nevertheless, patents from various pharmaceutical companies have continued to emerge, revealing diverse chemical classes of potent CCR3 antagonists and reflecting a continued broad interest in this area.
Subject(s)
Patents as Topic , Receptors, CCR3/antagonists & inhibitors , Animals , Humans , Interleukin-5/antagonists & inhibitors , Morpholines/pharmacology , Piperidines/pharmacology , Pyrrolidines/pharmacologyABSTRACT
The subventricular zone (SVZ) is the largest germinal zone in the mature rodent brain, and it continuously produces young neurons that migrate to the olfactory bulb. Neural stem cells in this region generate migratory neuroblasts via highly proliferative transit-amplifying cells. The Wnt/beta-catenin signaling pathway partially regulates the proliferation and neuronal differentiation of neural progenitor cells in the embryonic brain. Here, we studied the role of beta-catenin signaling in the adult mouse SVZ. beta-Catenin-dependent expression of a destabilized form of green fluorescent protein was detected in progenitor cells in the adult SVZ of Axin2-d2EGFP reporter mice. Retrovirus-mediated expression of a stabilized beta-catenin promoted the proliferation of Mash1+ cells and inhibited their differentiation into neuroblasts. Conversely, the expression of Dkk1, an inhibitor of Wnt signaling, reduced the proliferation of Mash1+ cells. In addition, an inhibitor of GSK3 beta promoted the proliferation of Mash1+ cells and increased the number of new neurons in the olfactory bulb 14 days later. These results suggest that beta-catenin signaling plays a role in the proliferation of progenitor cells in the SVZ of the adult mouse brain.
Subject(s)
Cell Proliferation , Lateral Ventricles/cytology , Signal Transduction , Stem Cells/cytology , beta Catenin/physiology , Aging/physiology , Animals , Cell Differentiation/physiology , Lateral Ventricles/metabolism , Lateral Ventricles/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Signal Transduction/physiology , Stem Cells/physiologyABSTRACT
As part of our investigation into the development of potent CCR3 antagonists, a series of piperidine analogues was designed and prepared. Exploration of the piperidine core examined both the basicity and the location of a nitrogen, as well as conformational variants. The bicyclo-piperidine 24c was found to be the most potent inhibitor of CCR3 with an IC(50) of 0.0082 microM in the binding assay and 0.0024 microM in the chemotaxis assay.
